Inclisiran, first developed by AlnylamPharmaceuticals, is a first-class siRNA drug, which can reduce LDL and C levels (about 50%). The pharmaceutical company obtained the exclusive global development and commercial authorization of Inclisiran, and Novartis acquired the pharmaceutical company and took Inclisiran into its pocket.
Lipid-lowering drugs are a big market. Lipitor of Pfizer has occupied the position of "drug king" with sales exceeding $ 100 billion for several years in succession, which is also the first molecule with annual sales exceeding $ 100 billion in drug history, and then fell off the throne because of "patent cliff".